- An approach that focuses on host factors that have not yet been explored in the active RSV therapeutic area
- Implementation plan from comprehensive analysis for host factors to identification of binding molecules involved in RSV life cycle
- A leading researcher with extensive experience in RSV research and nasal tissue host immune response research
Background & Technology
RSV is a respiratory tract infectious virus that has been linked to respiratory-related deaths in children under 6 months of age. In a global epidemiological study, annual RSV-related deaths (20,000-60,000) in persons under 5 years of age were higher than seasonal influenza virus (IAV)-related deaths (0.5-20,000), and the burden of disease in the elderly was similar to that of IAV. Although the development of treatments for RSV has been active, effective prevention and medication have not yet been established. The investigator would like to approach research and treatment with a particular focus on host factors, considering not only acute infection but also the refractoriness of repetitive otitis media induced after infection.
The concept of developing host-factor targeted therapy has the advantage of being a novel strategy for RNA viruses that are easily mutable, because drug-resistant viruses are less likely to emerge compared to viral structure-specific therapeutics. This research project is highly original and was conceived by the principal investigator while conducting translational research using human specimens from the study of chronic sinusitis. In addition, it is based on her clinical experience as an otolaryngology specialist and clinical geneticist, with a view to the practical application of new treatment methods developed as reverse translational research. Through exploratory studies, six genes have already been found to reduce pneumovirus infectivity titers. Future research plans include the identification of therapeutic targets through two approaches related to the RSV life cycle: 1) target discovery based on comprehensive genetic analysis, and 2) factor identification based on libraries of already approved drugs and compounds.
Ogasawara N et al., Mucosal Immunol. 2020, 13 (1):86-95. doi: 10.1038/s41385-019-0215-8
Ogasawara N et al., J Allergy Clin Immunol 2020, 145 (1):437-440. doi: 10.1016/j.jaci.2019.09.001
Ogasawara N et al., J Allergy Clin Immunol 2018;141(3):1147-1151. doi: 10.1016/j.jaci.2017.09.025
Ogasawara N et al., Allergy 2018; 73(11):2251-2254. doi: 10.1111/all.13552
Yamamoto K and Ogasawara N* et al., Microbiol Immunol. 2018;62(2):90-98. doi: 10.1111/1348-0421.12563
Yamamoto K, Yamamoto S, Ogasawara N* et al., Pharmacol Res 2016; 111:804-814. doi: 10.1016/j.phrs.2016.07.033
Noriko Ogasawara (M.D., PhD.) Sapporo Medical University School of Medicine, Department of Microbiology, Lecturer
We are interested in joint research, development collaboration, grant co-application, research investment or research support with companies interested in RSV therapeutics. We would like to exchange information and discuss the potential of this development theme.
Product No. ON-04016